Cognition TherapeuticsCGTX
About: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Employees: 25
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
290% more capital invested
Capital invested by funds: $1.99M [Q3] → $7.76M (+$5.76M) [Q4]
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
16.02% more ownership
Funds ownership: 10.6% [Q3] → 26.62% (+16.02%) [Q4]
10% more funds holding
Funds holding: 40 [Q3] → 44 (+4) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Chardan Capital Daniil Gataulin 18% 1-year accuracy 7 / 38 met price target | 2,467%upside $11 | Buy Maintained | 26 Feb 2025 |
B. Riley Securities Mayank Mamtani 20% 1-year accuracy 4 / 20 met price target | 250%upside $1.50 | Buy Upgraded | 19 Dec 2024 |
HC Wainwright & Co. Raghuram Selvaraju 34% 1-year accuracy 115 / 340 met price target | 1,300%upside $6 | Buy Maintained | 19 Dec 2024 |
Financial journalist opinion









